APA

Bachanova V., Marks D. I., Zhang M., Wang H., de Lima M., Aljurf M. D., Arellano M., Artz A. S., Bacher U., Cahn J., Chen Y., Copelan E. A., Drobyski W. R., Gale R. P., Greer J. P., Gupta V., Hale G. A., Kebriaei P., Lazarus H. M., Lewis I. D., Lewis V. A., Liesveld J. L., Litzow M. R., Loren A. W., Miller A. M., Norkin M., Oran B., Pidala J., Rowe J. M., Savani B. N., Saber W., Vij R., Waller E. K., Wiernik P. H. & Weisdorf D. J. (20140430). Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. : Leukemia.

Chicago

Bachanova V, Marks D I, Zhang M-J, Wang H, de Lima M, Aljurf M D, Arellano M, Artz A S, Bacher U, Cahn J-Y, Chen Y-B, Copelan E A, Drobyski W R, Gale R P, Greer J P, Gupta V, Hale G A, Kebriaei P, Lazarus H M, Lewis I D, Lewis V A, Liesveld J L, Litzow M R, Loren A W, Miller A M, Norkin M, Oran B, Pidala J, Rowe J M, Savani B N, Saber W, Vij R, Waller E K, Wiernik P H and Weisdorf D J. 20140430. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. : Leukemia.

Harvard

Bachanova V., Marks D. I., Zhang M., Wang H., de Lima M., Aljurf M. D., Arellano M., Artz A. S., Bacher U., Cahn J., Chen Y., Copelan E. A., Drobyski W. R., Gale R. P., Greer J. P., Gupta V., Hale G. A., Kebriaei P., Lazarus H. M., Lewis I. D., Lewis V. A., Liesveld J. L., Litzow M. R., Loren A. W., Miller A. M., Norkin M., Oran B., Pidala J., Rowe J. M., Savani B. N., Saber W., Vij R., Waller E. K., Wiernik P. H. and Weisdorf D. J. (20140430). Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. : Leukemia.

MLA

Bachanova V, Marks D I, Zhang M-J, Wang H, de Lima M, Aljurf M D, Arellano M, Artz A S, Bacher U, Cahn J-Y, Chen Y-B, Copelan E A, Drobyski W R, Gale R P, Greer J P, Gupta V, Hale G A, Kebriaei P, Lazarus H M, Lewis I D, Lewis V A, Liesveld J L, Litzow M R, Loren A W, Miller A M, Norkin M, Oran B, Pidala J, Rowe J M, Savani B N, Saber W, Vij R, Waller E K, Wiernik P H and Weisdorf D J. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. : Leukemia. 20140430.